Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan Set to Settle Off-Year Debate with “x1.0” Threshold for PMP Meds/Generics, “x0.5” for LLPs
December 20, 2024
- MHLW Proposes Setting Product Scope for Off-Year Revisions by Category
December 19, 2024
- MHLW to Disclose Company Names under Generic Index Rule Possibly in FY2026
December 19, 2024
- Japan Weighs Tweaking “x0.625” Threshold to Narrow Off-Year Revision Coverage
December 19, 2024
- Japan to Add Shingles Vaccines to NIP List from FY2025, Targeting Age 65
December 19, 2024
- MHLW Orders Label Revisions for SGLT2 Inhibitors, COVID Drugs, and More
December 19, 2024
- Japan Diet OKs FY2024 Supplementary Budget
December 18, 2024
- DPP to Co-Sponsor Bill to Make Drug Price Revisions a Biennial Event
December 18, 2024
- Ruling Party Discussions Progress with Off-Year Revisions as a Given
December 18, 2024
- Ruling Bloc’s Draft Budget Policy Says Off-Year Revisions Could Alter, but DPP Calls for Explicit Mention of Repeal
December 17, 2024
- LDP’s Tamura Renews Question over Product Coverage of Off-Year Revisions
December 16, 2024
- Discussions on Generic Company Indices Make Headway towards Full Rollout in Next Revision
December 13, 2024
- CDP OKs Bill to Scrap Off-Year Revisions, Aims for Diet Submission Soon
December 13, 2024
- Chuikyo Doctor Rep Positive on Industry’s Behavioral Changes after 2024 Reform
December 12, 2024
- JGA to Compile Interim Report on Generic Industry Revamp in May
December 12, 2024
- Hearing Leaves Chuikyo Mixed on Off-Year Scheme, Political Decision Ever More Likely
December 12, 2024
- Ex-Minister Takemi to Set Up Nonprofit to Bolster Pharma Innovation
December 11, 2024
- LDP Study Group Urges Health, Finance Ministers to Drop Off-Year Revisions
December 11, 2024
- PM Ishiba Elusive on Course of Off-Year Revisions: Diet Session
December 10, 2024
- Gene Therapies from Ferring, Ultragenyx in Line for Orphan Status, Moderna mRNA Drug Too
December 10, 2024
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…